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Background: Previous studies have shown that treatment with ergocalciferol in patients with CKD stage 3 + 4 is
not effective with less than 33% of patients achieving a 25-OH vitamin D target of >30 ng/ml. The aim of this study
was to test the response to cholecalciferol in CKD. We attempted to replete 25-OH vitamin D to a target level of
40–60 ng/ml using the response to treatment and PTH suppression as an outcome measure.
Methods: This retrospective cohort study identified patients (Stages 2–5 and Transplant) from 2001–2010 who
registered at the Chronic Kidney Disease Clinic. Patients received cholecalciferol 10,000 IU capsules weekly as initial
therapy. When levels above 40 ng/ml were not achieved, doses were titrated up to a maximum of 50,000 IU
weekly. Active vitamin D analogs were also used in some Stage 4–5 CKD patients per practice guidelines. Patients
reaching at least one level of 40 ng/mL were designated RESPONDER, and if no level above 40 ng/mL they were
designated NON-RESPONDER. Patients were followed for at least 6 months and up to 5 years.
Results: 352 patients were included with a mean follow up of 2.4 years. Of the CKD patients, the initial 25-OH
vitamin D in the NON-RESPONDER group was lower than the RESPONDER group (18 vs. 23 ng/ml) (p = 0.03).
Among all patients, the initial eGFR in the RESPONDER group was significantly higher than the NON-RESPONDER
group (36 vs. 30 ml/min/1.73 m2) (p < 0.001). Over time, the eGFR of the RESPONDER group stabilized or increased
(p < 0.001). Over time, the eGFR in the NON-RESPONDER group decreased toward a trajectory of ESRD. Proteinuria
did not impact the response to 25-OH vitamin D replacement therapy. There were no identifiable variables
associated with the response or lack of response to cholecalciferol treatment.
Conclusions: CKD patients treated with cholecalciferol experience treatment resistance in raising vitamin D levels
to a pre-selected target level. The mechanism of vitamin D resistance remains unknown and is associated with
progressive loss of eGFR. Proteinuria modifies but does not account for the vitamin D resistance.
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Vitamin D [25(OH)D] insufficiency and secondary hyper-
parathyroidism is widely prevalent in patients with chronic
kidney disease [1] including patients who have received a
renal transplant [2]. The Kidney Disease Outcomes Qual-
ity Initiative (K/DOQI) guidelines recommend measuring
PTH and initiating treatment of vitamin D insufficiency
starting with CKD stage 3 [3].
Dietary intake of vitamin D may originate from either
plant based sources (ergocalciferol, D2) or animal based
sources (cholecalciferol, D3). The metabolic pathways of* Correspondence: ls38@columbia.edu
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Active vitamin D2 and D3 both target the vitamin D
receptor initiating vitamin D regulated gene trans-
cription [4]. Achieving optimal levels of serum 25(OH)
D remains a challenge in patients with advanced chronic
kidney disease. Not only is 25-OH vitamin D purported
to have its own beneficial effects, but metabolism to cal-
citriol has been shown to reduce PTH levels [1,5]. The
National Kidney Foundation (NKF) guidelines state that
optimal 25(OH) D levels should be greater than 30 ng/mL
and should be repleted with oral ergocalciferol [3] while the
American Journal of Nutrition guidelines recommend levels
greater than 40 ng/mL [6,7]. There are no specific re-
commendations in the NKF/KDOQI guidelines regardingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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patients receiving dialysis. There is not much data available
to suggest exactly how much ergocalciferol should be
administered [8-10] and whether such therapy impacts
vitamin D and serum PTH concentrations. Zissman et al.
studied the response to ergocalciferol for CKD Stages 3 and
4 [11]. They found a partial reduction in PTH for patients
with Stage 3 CKD but not Stage 4 when repleted with ergo-
calciferol. Less than 33% of patients achieved a 25-vitamin
D (Vit D) target of >30 ng/ml and 50% did not respond to
treatment [11]. Al-Aly et al. found similar findings and
noted a similar lack of response to ergocalciferol [5].
Cholecalciferol (D3) is presumably more potent than
ergocalciferol (D2) [4,12,13]. The aim of this study was
to test the response to cholecalciferol in CKD. Similar to
that observed for ergocalciferol, suggested dosages for
repletion vary [14,15]. We attempted to replete 25-OH
vitamin D levels to a target of 40–60 ng/mL using the
response to treatment and PTH suppression as outcome
measures. The working hypothesis for this study was
that patients with more advanced CKD require signifi-
cantly higher dosages to achieve the pre-selected blood
level target. Patients with better kidney function would
respond more readily to vitamin D supplementation
compared to those with poorer function.
Methods
Patients
570 patients were identified from 2001 to 2010 who reg-
istered at the Chronic Kidney Disease (CKD) Clinic at
Columbia University Medical Center (CUMC). Patient
data measurements were electronically extracted from
the clinical data warehouse (CDW), the research database
of the Columbia University Medical Center (CUMC) of
the New York Presbyterian Hospital (NYPH) system. Data
extracted from this cohort included demographic infor-
mation, serum creatinine, 25-OH and 1,25-OH vitamin D
measurements, calcium, albumin, parathyroid hormone
levels, proteinuria levels (24 hr. urine protein or protein/
creatinine ratio) and other laboratory tests. Diabetes and
hypertension status was assigned from ICD-9 coding.
Study design
Patients received vitamin D repletion with cholecalcif-
erol 10,000 IU capsules weekly. Patients also received
dietary counseling to reduce daily calcium intake to less
than 500 mg and daily phosphate intake to less than
1000 mg. At each patient follow-up visit, the medication
list was reviewed and compliance was confirmed. When
levels of 25-OH vitamin D above 40 ng/mL were not
achieved, doses were titrated upwards over 6 months to
a maximum of 50,000 IU weekly. A step-wise protocol
was followed to increase the dosage of cholecalciferol.
Follow-up, repeat vitamin D levels, and dose adjustmentas needed was performed at regular intervals concurrent
with clinic visits at 1–4 month intervals. 25-OH vitamin D
levels were measured by a chemiluminescent immuno-
assay (ARUP Laboratories; Salt Lake City, UT). The same
laboratory and assay were used throughout the study
period.
Responsiveness, as measured by the change in 25-OH
vitamin D level, was the primary outcome measure.
PTH suppression was a secondary outcome measure.
Safety markers included hypercalcemia and hyperpho-
sphatemia. eGFR was calculated for patients using the 4
variable modified diet in renal disease (MDRD) equation
and extracted creatinine and demographic values [16].Study population
Patients who maintained 25-OH vitamin D levels ≥40 ng/
mL and never fell below this level were designated RE-
PLETE. When a patient’s 25-OH vitamin D level fell below
40 ng/mL, the patient was followed until a response was
noted (i.e. 25-OH vitamin D level ≥ 40 ng/mL). A response
was defined as achieving a level of at least 40 ng/mL in a
period no less than 6 months. Patients achieving vitamin
D levels of ≥40 ng/ml with cholecalciferol were designated
as RESPONDER. If the vitamin D level did not reach 40,
the patient was designated NON-RESPONDER. Patients
were excluded who had only one measurement of 25-OH
vitamin D during the study period, or who had no follow-
up beyond 6 months.Statistical analysis
Chi-squared or Fisher’s exact test was used to compare
categorical variables; t-test or Wilcoxon Rank Sum test
was used to compare continuous variables. Significance
was defined at a 95% confidence level for two-tail meas-
urement. Longitudinal effects of 25-OH vitamin D were
analyzed by a linear mixed effect model with random
intercept, which accounted for individual differences in
the initial outcome value. Analysis was performed to
adjust for varying follow-up times. A time adjusted vari-
able was introduced to reduce observer bias which
decreased the N. Repeated measures ANOVA was not
utilized due to missing values, unequal time differences
between data points, and the inability to adjust for a
number of covariates.
Statistical analysis was performed using SAS version
9.2 (SAS Institute Inc., Cary, NC). Columbia Univer-
sity Medical Center Institutional Review Board, FWA#
00002636, approved this protocol (IRB Protocol #
AAAD8498) in compliance with the Helsinki Declaration
from 8/6/09 to present. There was no interaction or inter-
vention with any human subjects. This data is not publicly
available. The IRB granted a waiver of consent for this
retrospective cohort study.
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Of the 570 patients identified from 2000 to 2010 who were
treated at the Chronic Kidney Disease Clinic, 127 were
initially excluded (Figure 1). 8 patients were analyzed who
consistently maintained 25-OH vitamin D levels > 40 ng/
mL. These patients were designated REPLETE. Over the
10 year period, the 25-OH vitamin D level fell below
40 ng/mL in 221 patients, and was successfully repleted
with cholecalciferol supplementation. These patients were
designated RESPONDER. Supplementation with cholecal-
ciferol failed to achieve a level of 40 ng/ml or greater in
169 patients who were designated NON-RESPONDER.
Table 1 shows the distribution of patients between 3
groups: CKD, post-transplant (TXP), and renal replace-
ment therapy (RRT). Statistically significant differences
between groups were observed in age (p < 0.001) and for
hypertensive renal disease (p = 0.03).
Table 2 shows the distribution of patients by vitamin D
status. Of the 309 CKD patients, 54.7% of CKD patients
are RESPONDER compared to 42.7% NON-RESPONDER
(p < 0.001). 81.4% of the 43 TXP patients were RESPON-
DER compared to 18.6% NON-RESPONDER. Among all
patients, unadjusted initial values for eGFR, Albumin,
Phosphate, and 1, 25-OH vitamin D were significantly dif-
ferent between the RESPONDER and NON-RESPONDER
groups. In the patients with CKD stages 3–5, the unadjus-
ted initial mean eGFR and 25-OH vitamin D were lower
in the NON-RESPONDER compared to the RESPONDER
(p < 0.03 and p < 0.001, respectively). Table 3 shows the
initial values of the subset of patients for whom protein-
uria data was available. Significant differences in initialFigure 1 Study flow diagram.mean 25-OH vitamin D (p = 0.02) and mean proteinuria
(p < 0.004) were noted.
Figure 2 depicts the relationship between log eGFR ver-
sus time in the RESPONDER and NON-RESPONDER
groups for patients where the 25-OH vitamin D was below
40 ng/mL for CKD patients Stage 3–5 (N = 240) and treat-
ment was initiated. In this model adjusted for Age, Sex,
Race, Diabetes status and Hypertension status, the initial
eGFR is not different between the NON-RESPONDER
and RESPONDER groups (p = 0.77). Over the follow-up
time the eGFR for NON-RESPONDER (N = 108) is lower
and declines over time (coefficient −0.007) compared to
RESPONDER with a higher eGFR which increases over
time (coefficient 0.004) (p < 0.001). No differences in the
distribution of CKD stages between the two groups were
noted (p = 0.21).
Figure 3 depicts the relationship between PTH versus
time in the RESPONDER and NON-RESPONDER
groups for patients where the 25-OH vitamin D was
below 40 ng/mL for CKD patients Stage 3–5 (N = 212)
and treatment was initiated. There is no difference in
PTH over time between the NON-RESPONDER and
RESPONDER (p =NS). Similarly, there is no difference
between 1, 25-OH vitamin D levels versus time and
25-OH vitamin D when the level was below 40 for CKD
patients Stage 3–5 and treatment was initiated (figure not
shown).
Figure 4 illustrates the Log Proteinuria over Time by
Group for CKD patients with eGFR < 60 ml/min/1.73 m2.
Proteinuria increases for 11 months in the NON-RE-
SPONDER and decreases for 21 months in the
Table 1 Demographics
CKD Transplant RRT P value‡
N 309 43 46
Males 162 (52.4%) 24 (55.8%) 25 (54.4%) 0.90
Age† 66·4 (14.2) 51·6 (11.9) 58.1 (17.5) <0.001
Diabetes, only 1 (0.3%) 0 (0·0%) 0 (0.0%) 1.0
Hypertension, only 123 (39.8%) 25 (58.1%) 15 (32.6%) 0.03
Diabetic and hypertensive 171 (55.3%) 18 (41.9%) 29 (63.0%) 0.12
Non-diabetic and non-hypertensive 14 (4.5%) 0 (0.0%) 2 (4.4%) 0.44
†Categorical variables are expressed as count (%); age as mean (SD); all other continuous variables as median (25th percentile-75th percentile).
‡Based on chi-squared or Fisher’s exact test for categorical variables; t-test or Wilcoxon Rank Sum test for continuous variables.
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teinuria by Group for CKD patients with eGFR < 60 ml/
min/1.73 m2. For all levels of proteinuria, the eGFR is
lower in the NON-RESPONDER compared to the RE-
SPONDER group.
Discussion
Vitamin D insufficiency is highly prevalent in the CKD
population. Across the United States prevalence ranges
up to 70% [1]. This is consistent with our study in which
98% of all patients studied had vitamin D levels less than
40 ng/mL. Zisman suggested target levels of vitamin D in-
adequately suppress PTH in patients with CKD especiallyTable 2 Primary and secondary outcomes
Non-responder Respond
N 169 221
Males 86 (50.9%) 119 (53.9
Age† 62.5 (15·5) 64.9 (14
Diabetes, only 0 (0.0%) 1 (0.45%
Hypertension, only 62 (36.7%) 97 (43.9
Diabetic and hypertensive 102 (60.4%) 113 (51.1
Non-diabetic and non-hypertensive 5 (3.0%) 10 (4.5%
CKD 132 (78.1%) 169 (76.5
Transplant 8 (4.7%) 35 (15.8
RRT 29 (17.2%) 17 (7.7%
eGFR 30.0 (22.0) 36·0 (27
PTH 99.0 (137.0) 86·5(102
Albumin 3.9 (0.6) 4·3 (0.4
Initial mean phosphate 3.8 (1.1) 3·5 (0.9
Initial mean 1,25-OH vitamin D 20.5 (18.0) 30.0 (19
For CKD stage
Initial mean eGFR 28·3 (11.5) 31·5 (11
Initial mean 25-OH vitamin D 18·3 (9.0) 23·6 (9.
†Categorical variables are expressed as count (%); age as mean (SD); all other contin
‡Based on chi-squared or Fisher’s exact test for categorical variables; t-test or Wilcox
†At time of 25-vitamin D grouping.
‡Prior to 25-vitamin D grouping.
The boldface items indicate values less than 0.05.those with more advanced impairment in kidney function
[11]. In the absence of published, definitive evidence based
guidelines, our clinical practice guideline was to target
vitamin D to levels of 40–60 ng/mL. This target was
chosen based on a review of consensus opinions in the
nephrology and endocrine communities [17,18]. We noted
that this was exceedingly difficult to achieve in our po-
pulation, which included both CKD and post-transplant
patients.
One aim of our study was to demonstrate that chole-
calciferol is a more potent vitamin D precursor therapy
in CKD patients compared to ergocalciferol, which was
used in previous studies [11]. What we uncovered is aer Replete P Value‡ (responder vs. non-responders)
8
%) 6 (75.0%) 0.56
·9) 64.5 (18·0) 0.12
) 0 (0.0%) 1.0
%) 4 (50.0%) 0.15
%) 3 (37.5%) 0.07












uous variables as median (25th percentile-75th percentile).
on Rank Sum test for continuous variables.
Table 3 Outcomes by group
Non-responder Responder P value
*Initial Mean 25VitD 19 ng/mL 23 ng/mL 0.02
*Initial Mean Proteinuria 1.47 g/day 0.89 g/day <0.004
*Initial Mean eGFR (ml/min/1·73 m2) 27 31 0.09
*Initial PTH 110 pg/mL 100 pg/mL 0.38
*Not adjusted for follow-up time. Closely concurrent lab values were measured with initial 25-OH Vitamin D.
The boldface items indicate values less than 0.05.
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which we suggest is associated with a progressive decline
in renal function over time. Our study has demonstrated
that CKD patients treated with cholecalciferol, similar to
ergocalciferol, experience treatment resistance in raising
vitamin D levels to a pre-selected target level. Although
multiple studies have suggested that cholecalciferol is
more potent [19,20], we could not find evidence that the
response to treatment with cholecalciferol is any better
than with ergocalciferol. We did however, find two dis-
tinct groups in our population: 1) those who responded
to treatment (RESPONDER) and 2) those who did not
(NON-RESPONDER). Among all the patients, initial
laboratory values which were unadjusted for follow-up
for the NON-RESPONDER group were significant for aFigure 2 Log eGFR over time by group for CKD Stages 3–5. Log eGFR
N = 108 Non-responders and 132 Responders. No differences in the distribulower initial eGFR, higher PTH, lower albumin, higher
phosphate, and lower 1, 25-OH vitamin D.
Similar to other studies with ergocalciferol, our popu-
lation received a vigorous supplementation protocol with
cholecalciferol. This regimen resulted in a significant in-
crease in vitamin D levels only for a specific population:
RESPONDER. This group has unique characteristics
compared to those whose levels did not increase to the
pre-selected target level of greater than 40 ng/mL. In the
CKD Stage 3–5 group, unadjusted initial mean eGFR and
25-OH vitamin D levels were higher in the RESPONDER
group. When adjusted for time for CKD patients with an
eGFR < 60 ml/min/1.73 m2 the initial eGFR in RESPON-
DER and NON-RESPONDER groups is indistinguishable
(Figure 2). The data suggests that the eGFR for theover Time by Group for CKD patients with eGFR < 60 ml/min/1.73 m2.
tion of CKD stages between the two groups were noted (p = 0.21).
Figure 3 Log PTH over time by group for CKD Stages 3–5. Log PTH over Time by Group for CKD patients with eGFR < 60 ml/min/1.73 m2.
N = 93 Non-responders and 119 Responders. There is no difference in PTH between the Non-Responders and Responders over time (p = NS).
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whereas the NON-RESPONDER group has a progres-
sively worsening eGFR. This association however may
represent the possibility that RESPONDER group overall
had a better health status (i.e. higher albumin, lower phos-
phorus, higher initial eGFR). Adherence to the treatment
regimen may possibly distinguish the RESPONDER
and NON-RESPONER groups. However, compliance was
assessed for all clinic patients on each visit and this effect
is unlikely to be caused by non-adherence.
There are numerous hypotheses as to why one group
might respond or not respond. Timing of administration
or changes in intestinal absorption could account for a
difference. In our study, transplant patients have a lower
prevalence of NON-RESPONDER compared to the CKD
population which may indicate that “healthy kidneys”
play a role. Traditionally, calcidiol (25-OH vitamin D)
levels are thought to be indicative of vitamin D body
stores and correlate with nutritional status, whereas calci-
triol (1, 25-OH vitamin D) levels are typically preserved
despite the nutritional state [21-23].
It is possible that proteinuria with the loss of vitamin
D binding protein may account for both the low levels
of vitamin D observed and the vitamin D resistance in
CKD [24-26]. Others have reported a favorable effect of
vitamin D repletion on nephrotic range proteinuria[27,28]. Our data shows that response to treatment with
cholecalciferol is associated with a lower initial level of
proteinuria (Table 3) and a better preservation of eGFR
(Figure 2). For any given level of proteinuria, the eGFR
is lower in the NON-RESPONDER compared to the
RESPONDER group (Figure 4). Our 3-way mixed model
demonstrates that proteinuria modifies the time relation-
ship between eGFR and the RESPONDER vs. NON-
RESPONDER groups (p = 0.03), however it does not
predict the change in eGFR over time. Proteinuria modi-
fies, but does not account for, the vitamin D resistance.
Hormonal regulation and dysregulation are the hallmark
features of CKD. The target of the hormonal dysregulation
is centered on maintaining the serum calcium and phos-
phate concentrations in what we think is a normal target
range well into the advanced stages of CKD. Reductions in
1,25-OH vitamin D are the single most prevalent abnor-
mality characterizing CKD [29,30]. Concurrent with this
reduction is the progressive elevation of FGF23, a hor-
mone produced in the osteocyte of bone whose regulation
has remained elusive [31,32]. PTH elevations are also pro-
gressive in CKD as a consequence of the reductions in
1,25-OH vitamin D over time. However, treatment with
vitamin D also elevates FGF23 levels by virtue of a well
described feedback loop [33]. High FGF23 levels have
been shown to be a marker of poor patient outcome in
Figure 4 Log Proteinuria over time by group for CKD patients with eGFR < 60 ml/min/1·73 m2. Log Proteinuria over Time by Group for
CKD patients with eGFR < 60 ml/min/1.73 m2. N = 69 Non-responders and 76 Responders. (p < 0.05). Proteinuria increases for 11 months in
Non-responders. Proteinuria decreases for 21 months in Responders.
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study in a CKD model showed that targeted reduction in
FGF23 resulted in increased mortality further complicat-
ing our understanding of this complex physiology [37]. In
large data base studies of patients with CKD and ESRD,
treatment with vitamin D has been shown to promote a
survival advantage [38-42]. Calcitriol in high dose has
been shown to promote vascular calcification in animal
models of CKD [43-45] and a recent meta-analysis sug-
gests that low-dose paricalcitol may do the same [46].
Thus the clinician in practice is faced with the clinical
conundrum and safety concern of how much vitamin D to
administer to patients with vitamin D insufficiency and to
aim for what vitamin D target level in order to achieve the
best clinical outcome. In our current understanding of this
complex system, treatment with 25 vitamin D precursors
and active vitamin D analogues is initiated to target PTH
primarily to limit the progressive bone injury that occurs
with elevated PTH levels. The PTH target is also a matter
of much debate in the nephrology community [47].
The understanding of the interaction between active
and inactive forms of vitamin D and PTH has improved
immensely with the identification of FGF-23 [48], Klotho
[49,50], and CYP27B1 [51]. Some have suggested that
high doses of vitamin D supplementation similar to whatwas administered in our study induce the catabolic cyto-
chrome P-450 enzyme CYP24A1 [52]. This may explain
why high dose vitamin D supplementation and previous
attempts of vitamin D repletion at lower dosage have
failed [53]. Another potential mechanism which en-
hances vitamin D catabolism relates to the progressive
elevation of the phosphaturic FGF23 noted in CKD.
Both the administration of vitamin D and an elevated
FGF23 in CKD have the potential to hyper-catabolize
vitamin D in all forms. Therefore, an elevated FGF-23
may limit the response to a preselected vitamin D target
level (i.e. vitamin D resistance) through this hypercatab-
olism mechanism.
Limitations of the study include the retrospective nature
of the study design. Despite our best efforts to ascertain
medication compliance, some patients may still have not
taken their cholecalciferol. Seasonal differences were not
investigated due to the long follow-up period of each
patient. Cumulative doses of cholecalciferol given were
not available. Weight, changes in weight, or the role of
obesity in both groups was not ascertained. Given the low
numbers of patients receiving home hemodialysis (3), out-
patient center hemodialysis (23), and peritoneal dialysis
(20) in our study, they were grouped together as renal
replacement therapy and excluded from the study analysis.
Figure 5 Log eGFR vs. log proteinuria by group for CKD patients with eGFR < 60. Log eGFR vs. Log Proteinuria by Group for CKD patients
with eGFR < 60 ml/min/1.73 m2. N = 47 Non-responders and N = 45 Responders. For all levels of proteinuria, eGFR is lower in the Non-responders.
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these groups however the benefits of supplementation
have been previously suggested in the PD population [6].
Information regarding malabsorption syndromes (such
as by gastric bypass) of the patients in the study are
unknown.
Multiple non-renal associations have been described
between vitamin D: cardiovascular disease [54], immune
function [55], asthma [56], cancer [57], and autoimmune
diseases [58]. Low 25-OH vitamin D has also been sug-
gested as a marker of mortality in the critical care setting
[59]. Whether vitamin D becomes a marker of nutrition
or of something more, monitoring of blood levels and
targeted replacement therapy in the CKD population may
give a hint of future CKD status. Our study is unable to
identify suitable markers that could advance the state of
knowledge and distinguish which patients will be in a
future RESPONDER group and which will not.
Conclusion
The clinical implications of a replete 25-OH vitamin D
level remain unknown. Responders appear to stabilize or
increase their eGFR over time, however the Non-Re-
sponders display a deterioration of eGFR over time. Pro-
teinuria modifies the response to cholecalciferol initially
but does not predict the change in eGFR over time. The
mechanism of the treatment resistance (RESPONDER vs.NON-RESPONDER) is also unknown and could be caused
by a change in vitamin D metabolism (decreased synthesis
or increased catabolism). Both of these effects could be
mediated by the progressive increase of FGF-23 levels
observed in CKD. Further research is necessary to test this
hypothesis and to identify predictive variables that could
be used for prognostic guidance.
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